Abstract: Age-related macular degeneration (AMD) compromises quality of life. However, the available therapeutic options are limited. This has led to the identification of modifiable risk factors to prevent the development or alter the natural course and prognosis of AMD. The identification and modification of risk factors has the potential for greater public health impact on reducing morbidity from AMD. Likewise, identifying the imaging clues and genetic clues could serve as a guide to recognizing the propensity for progression to severe and end stages of the disease. Several attempts, both successful and unsuccessful, have been made for interventions that could delay the progression of AMD. Of these, pharmacological interventions have shown promising results. The Age-Related Eye Disease Study 1 and 2 have shown the beneficial role of antioxidants in a selected group of patients.
T
here has been an increase in longevity and, therefore, an increase in the proportion of the aging population.
1 For instance, by 2025, the proportion of the geriatric population has been projected to increase to more than 1.2 billion worldwide, of which, about 70% will be residing in developing countries.
2 As a consequence, there may be an increase in the prevalence of agerelated macular degeneration (AMD). Early AMD includes the presence of drusen and/or retinal pigment epithelium (RPE) abnormalities; late AMD, in addition, includes geographic atrophy (GA) of the RPE or choroidal neovascular complex (CNV) .
The prevalence of AMD shows variations among Asian, Western, and European populations (Fig. 1 ). The prevalence rates of late AMD are similar between European (2.2-2.5%), Asian (0.1-1.9%), and North American studies (1.1-2.1%). Similarly, the prevalence of early AMD is comparable between the European (15.4-29.5%) and North American studies (14.1-20%). The differences in prevalence in different populations could be explained partly by genetic differences. For example, the frequency of the C-risk allele of the Y402H polymorphism is disproportionately much lower in Japanese when compared with whites (7% vs 34%). 3 The progression from early to late AMD varies based on certain clinical characteristics. In the Beaver Dam Eye Study, 4 the 15-year incidence of neovascular AMD was 2% in eyes with medium-sized drusen and 10% in eyes with large drusen. The incidence doubled with an increase in the size of the lesion (>700 µm area) and in the presence of bilateral large drusen. In the presence of bilateral large drusen, 32% without RPE alterations and 45% with at least unilateral RPE alteration developed CNV. The risk was higher in those who had geographic atrophy: 16% if the other eye had no neovascular disease and 36% when the other eye had a neovascular disease. In eyes with drusenoid pigment epithelial detachment (PED), over 10-year follow-up, nearly 55% develop GA and 40% develop neovascular AMD. In patients with late AMD in 1 eye, the risk of worsening in the other eye depends on the drusen number, size, and confluence. The presence of subretinal drusenoid deposits (reticular pseudodrusen) are an independent predictive factor in progression to advanced AMD. Pumariega et al 5 found that every third individual with these lesions progressed to late AMD over a 3-year follow-up.
The morbidity associated with AMD along with the limited therapy available has led to the investigation of risk factors for further prevention. In this regard, several attempts, both successful and unsuccessful, have been made for interventions that could delay the progression of AMD. Of these, pharmacological interventions have shown promising results.
Prevention of AMD: interventions for risk fActors

Dietary factors
Dietary supplementation represents one of the few modifiable factors for AMD and has been known to significantly delay progression, especially in dry AMD.
6 Among the well-investigated factors are oral antioxidant supplements. Of which, lutein and zeaxanthin (L&Z) are of interest, wherein greater levels of L&Z in the serum are associated with a 26% reduced chance of late AMD, 7, 8 but the association was not significant for early AMD.
In contrast, the Rotterdam Study examined the association between intake of dietary nutrients and lower risk of AMD. 9 The study observed that a higher dietary intake of nutrients such as L&Z, beta carotene, omega-3 fatty acids, and zinc reduced the risk of early AMD. Other studies 10,11 examined the effects of carotenoids and consumption of vitamins A, C, and E on AMD. Subjects with the highest tertile of intake of L&Z had a lower risk of neovascular AMD, and those with above medium intake had lower risk of reticular drusen.
10 A higher quintile of carotenoid
11
At the retinal level, early studies have shown that the macular pigment by its inherent protective nature may offer protection against AMD and that dietary supplements may improve macular pigmentation. 13, 14 However, a recent clinical trial observed an improvement in plasma levels of lutein, zeaxanthin, and ω-3 polyunsaturated fatty acids after 6 months but the pigmentation at the macula did not improve. 15 It has been observed that a minimum of 1-2 years is required for any appreciable improvement in visual function to be observed.
16,17
Lifestyle
Smoking
The association between smoking and AMD is widely recognized. [18] [19] [20] Longitudinal studies have demonstrated that current smoking is a risk factor for progression from minimal AMD to moderate early AMD. A cross-sectional study reported past smoking to be associated with AMD, especially in the rural community. 21 Greater number of pack-years smoked is associated with transition from no AMD to minimal early AMD and from severe early AMD to late AMD. 22 The exact mechanism has not been identified, but oxidative stress and changes to retinal and choroidal blood flow and endothelial reactivity have been proposed as a likely mechanism 23 in addition to atherosclerotic mechanisms. The findings may have implications in anti-vascular endothelial function therapies.
24,25
Tobacco
Tobacco use is a widespread problem. In India, nearly 30% of women and about 60% of men use smoked tobacco products such as cigarettes, bidis or cheroots, or smokeless tobacco such as chewed or snuff type. The use of smokeless tobacco is higher than smoked tobacco in South Asia and the usage is the same in men and women.
26-29 Tobacco consumption is associated with a wide range of systemic and ocular morbidities. A study 21 in the Indian population recently reported that smokeless tobacco rather than smoked tobacco is associated with both early and late AMD in both rural and urban populations. Another recent study 30 reported that the use of smokeless tobacco (as chewed and/or snuff) compared with no use is associated with late AMD; the study also examined the pack-years of use of smokeless tobacco but the association was not significant for early or late AMD. Both studies are not only timely but much needed for the Indian population. The exact mechanism is not clear. However, betel/areca nuts have arecoline (a major alkaloid) and polyphenols that possess carcinogenic, genotoxic, and mutagenic potential that may be related to AMD. 31 Further studies on various forms of tobacco and their influence on retinal and ocular health may be valuable.
Sleep Pattern
Inadequate or excess sleep is associated with adverse health outcomes. Longer sleep duration (>8 hours) has been linked with geographic atrophy 32 but not with early or neovascular AMD in a cross-sectional clinic-based questionnaire study. Similarly, short sleep duration is reported to be associated with neovascular AMD. 33 The decreased sleep efficiency in subjects with late stages of AMD has been attributed to the dysfunction of the intrinsically photosensitive retinal ganglion cell function.
34
Obesity
Excess body weight or obesity represents a threat for various systemic diseases. The relationship between obesity and AMD has been explored in many cross-sectional 35, 36 and longitudinal studies 37 using body mass index for defining obesity. However, waisthip ratio (WHR) and waist circumference have been reported as more reliable indicators of abdominal obesity when compared with body mass indices. It has been demonstrated that a higher WHR is associated with a greater risk of AMD progression. In addition, a reduction in the WHR is reported to be associated with decreased odds of AMD after 6-year follow-up.
Light Exposure
Ultraviolet (UV) rays and blue light cause damage to the retina. 39 These observations have led to the notion that solar radiation, either UV or visible, may play an important role in the etiology of AMD. Analysis of the National Health and Nutrition Examination Survey suggested that light-induced damage is associated with an apparent increase of AMD in aphakic eyes as the normal crystalline lens filters the damaging spectrum of the light.
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Spectral Filtering IOLs
In theory, a link has been proposed between phototoxicity and eyes after cataract surgery. 41 The yellowing of the crystalline lens with age blocks the blue light of the spectrum in the range of 400-500 nm. The transparent nature of intraocular lenses (IOLs) 42 makes the retina more exposed to visible light 43 and, therefore, susceptible to damage from visible light. 44 Yellow IOLs partially attenuate violet light (400-440 nm) 45 and block 50% of blue light at 450 nm and 25% at 480 nm. In contrast, conventional transparent IOLs transmit 90% of light (400 nm). 42 Therefore, these yellow IOLs may theoretically protect the macula from phototoxicity.
It is proposed that yellow IOLs attenuate visual performance under scotopic conditions because blue light, which is more informative in this environment, is being partially filtered. 42 However, in subjects who had undergone bilateral yellow IOL implantation, no significant changes were observed. 46 Hence, for most patients a yellow IOL may offer theoretical protection from AMD.
systemic Diseases
Hypertension
A small but statistically significant relationship has been observed between exudative AMD and systemic hypertension and antihypertensive medication 47 in cross-sectional population-based studies.
47-49 However, the association was not significant for dry AMD.
49 Arteriovenous nicking, a clinical feature in hypertension, is associated with an increased risk of incident AMD. 50 Reduction of systolic blood pressure below 160 mm Hg and diastolic blood pressure below 100 mm Hg can reduce the risk of progression to wet AMD.
Diabetes Mellitus
A few studies observed a positive association between diabetes and/or higher glycemic levels and AMD. 51, 52 The big challenge is the uncertainty in diagnosing AMD in the presence of diabetic retinopathy. Additionally, many studies of AMD exclude persons with diabetic retinopathy. This could potentially undermine the association between AMD and diabetes in the literature. However, there is still is evidence from prospective cohort studies 53, 54 that good glycemic control can aid in the prevention of AMD.
Cardiovascular Diseases
Studies found a relationship between AMD and clinical features of cardiovascular disease. 55, 56 The presence of plaques at the carotid bifurcation and in the common carotid artery is associated with a 4.5-fold and a 2-fold increased risk of late AMD, respectively. 57 Occurrence of AMD is positively correlated with the degrees of retinal arteriosclerosis. 58 The association between AMD, dietary fat, and cholesterol levels may be related to atherosclerosis.
59
Controlling cardiovascular risk factors and lipid levels may help in the prevention of AMD.
Prevention of Progression of the DiseAse:
interventions to iDentify or PreDict DeveLoPMent of LAte AMD screening tests
Amsler Chart
Amsler charts were named after Marc Amsler in 1947 to record subjective difficulties in macular diseases. 60 Amsler's work identified that patients with macular disorders often have symptoms preceding the signs. In addition to this, the easy availability of Amsler grids makes them viable tools for screening for macular disorders at an early stage.
In a systematic review 61 of 12 studies, Amsler charts showed a good specificity (0.85 to 1.0) but variable sensitivity (0.34 to 1.0). The reason for the variable sensitivity has been proposed to be the extraordinary capacity of the human brain to process and comprehend missing information (in this case, the missing lines).
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Preferential Hyperacuity Perimetry
Hyperacuity or vernier acuity is defined as the ability to perceive a difference in the relative spatial localization of 2 or more visual stimuli. 63 In advanced AMD, the shifting of the position of photoreceptors is reported to be the cause for the perception of an object location that is different from its original location. This perceived shift could be the likely explanation for metamorphopsia and can be documented by the preferential hyperacuity perimetry (PHP). 63 The PHP presents stimuli with artificial distortions of different amplitudes and arrives at an estimation based on probability. Later on, a home-based device was developed that took into consideration the size of the instrument, lighting requirements, and infrared sensors for accurate head position. 64 This device was then evaluated in the HOME (Home Monitoring of the Eye) study trial, which included 44 Age-Related Eye Disease Study 2 (AREDS2) clinical centers. 65 Participants who had either large drusen in both eyes or large drusen in 1 eye and advanced AMD in the fellow eye were provided specific instructions for self-monitoring at home, which included the Amsler grid.
Thirty-eight percent of 1970 participants were randomized to device monitoring and another 38% to standard care. In the device group, the decrease in visual acuity from baseline to CNV detection was smaller [median, −4 (−11.0, −1.0) letters] compared with the standard care group [median, −9 (−14.0, −4.0) letters] (P = 0.021). The study also found that 87% of eyes that used the device maintained a visual acuity of 20/40 or better compared with 62% in the standard care group (P = 0.014).
Shape-Discrimination Hyperacuity
Shape-discrimination hyperacuity (SDH), as the name suggests, involves the differentiation of shapes. Wilkinon et al 66 observed that humans can identify sinusoidal deformation better than circularity. In addition, detection of the threshold for radial deformation is a form of hyperacuity and may be utilized in examining the integrity of photoreceptor mosaic in patients with AMD.
My VisionTrack (Vital Art and Science, Dallas, TX) introduced SDH testing with a smartphone application. Wang et al 67 utilized the app and observed that, of the 37 subjects with AMD, SDH measurements were worse in patients with advanced AMD than intermediate AMD.
Macular Mapping Test
The Macular Mapping Test (MMT) is a convenient tool to quantitatively assess the residual vision in patients with maculopathies. The MMT scores have been compared between healthy and AMD eyes and it was reported that it is suitable for monitoring deterioration of disease.
68,69
Noisefield (Entoptic) Perimetry
This technique uses random patterns of visual noise. The test comprises small flickering black and white dots of a high frequency much like the "static" or "noise" in television. The patient is asked to report darker or lighter areas or those with less movement while fixating on a central target. The test is reported to have 100% specificity and 82% specificity for detecting AMD in general, 70 with 70% or more sensitivity for early AMD and 90% or more for moderate and late stages. Figure 2 shows the clues based on fundus evaluation and the corresponding risk for geographic atrophy or choroidal neovascularization.
clinical clues of Progression
imaging clues of Progression
There is a paucity of data regarding the utility of fundus autofluorescence (FAF) imaging with respect to early identification of AMD. In patients with exudative AMD in one eye and early AMD in the other eye, Smith and colleagues 71 observed no FAF abnormalities in the eye with early AMD. In contrast, the work by Spaide 72 demonstrated large areas of abnormal FAF in the fellow eyes with early AMD in patients with unilateral exudative AMD. Einbock et al 73 in a longitudinal study found that the patchy pattern in FAF in eyes with early AMD may be a marker for progression to late AMD. Optical coherence tomography (OCT) features of AMD have been documented as predictors of AMD progression over 5 years in a recent study. For instance, intraretinal changes, hyperreflective foci, and atrophy of the RPE are reported to be qualitative predictors of AMD progression. In terms of quantitative OCT features, volume of the RPE-drusen complex per 10 -1 mm 3 and thinning per 10 -3 mm 3 are reported to be predictive of AMD progression.
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Imaging of dry AMD using spectral domain optical coherence tomography provides a reliable algorithm for the accurate determination of drusen area and volume, along with the quantification of GA area. This would provide metrics for the defining features of dry AMD that could be followed over time.
genetic clues of Progression
Studies have identified some genetic factors in AMD. For instance, the complement factor H (CFH) Y402H polymorphism is associated with AMD. Age-related macular degeneration has a complex genetic composition but with somewhat identical phenotypes.
Independent studies published in the year 2013 on the AREDS subgroups suggest that genetic factors may be used for selecting subjects for nutritional supplementation and therapy. 37 However, another study conducted in a subset of 526 AREDS subjects reported that genetic testing is not beneficial for nutritional therapy in subjects with AMD.
37 Thus, the use of genetic testing as a routine is not supported in the literature. and extracellular matrix to facilitate migration of vascular endothelial cells into the tissue stroma in angiogenesis. The Anecortave Acetate Risk-Reduction Trial (AART) was designed to demonstrate that posterior juxtascleral depot of anecortave acetate at 6-month intervals is safe and effective in preventing the progression of dry to wet AMD. However, the study was terminated prematurely, with no definite results concluded.
role of Laser
Laser photocoagulation entails laser burns being applied to the retina, either directly to the drusen or following predefined patterns. Argon, krypton, dye, or diode lasers have been used with varying levels of energy. Subthreshold laser therapy aims at reducing the damage to the retinal tissue by ensuring minimal energy spread. This is achieved by reducing the duration of laser exposure and operates with a subvisible clinical endpoint. A subset of this technique is micropulse photostimulation that delivers light energy with very short impulses targeting the RPE only, sparing the neurosensory retina. Studies are investigating the prophylactic efficacy of nanosecond laser pulses.
A recent Cochrane meta-analysis of 11 well-conducted studies involving 3580 eyes of 2159 participants found that prophylactic laser treatment did not reduce the development of choroidal neovascular membrane at 2 years' follow-up. 79 Interestingly, prophylactic laser therapy led to drusen reduction but had no effect on visual acuity loss of 3 lines or more.
role of Pharmacological treatment
The influence of vitamins C and E, beta carotene plus zinc, zinc only, and antioxidants only on AMD progression and visual acuity was examined in the AREDS1 multicenter trial.
80 When compared with the placebo group, patients with intermediate AMD or unilateral late AMD had a lower odds for development of late AMD in all 3 groups; maximum benefit was seen in the antioxidants plus zinc group.
The recommendations of AREDS1 included the following: (a) individuals aged 55 years or more should have dilated fundus examinations to assess the risk of developing advanced AMD; (b) individuals with unilateral and/or bilateral intermediate AMD and unilateral advanced AMD, and with no contraindication such as smoking, should consider taking a combination of antioxidants plus zinc. However, it was not recommended for individuals with early AMD.
In AREDS2, a randomized multicenter clinical trial was designed to address the following: (1) role of lutein, zeaxanthin, and omega-3 fatty acids [docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)] in preventing the development of late AMD; (2) effect of possible deletion of beta carotene and lowering daily dose of zinc from 80 mg to 25 mg.
81
A total 6916 eyes of 4203 AREDS2 study participants were randomized to placebo, L&Z, DHA, and EPA. A subsequent randomization was done to the above 4 formulations of the original AREDS supplement but with fixed doses of vitamins C, E, and copper: (1) original AREDS supplement; (2) AREDS supplement minus beta carotene; (3) AREDS supplement with lesser dose of zinc; or (4) both without beta carotene and with lesser dose of zinc.
In the primary randomization, rates of progression to late AMD over 5 years were 31% for original AREDS supplement, 29% for L&Z, 31% for DHA plus EPA, and 30% for L&Z plus DHA and EPA. Thus, there were neither benefits nor adverse effects of adding L&Z, omega-3 fatty acids, or their combination on the progression to late AMD. 82 However, in the secondary randomization, more participants in the group that consumed supplements with beta carotene developed lung cancer than those who did not [23 (2.0%) vs 11 (0.9%); P = 0.04; 91% of whom were former smokers). Although lutein and zeaxanthin did not have any additional advantage, the greater chances of lung cancer in current and past smokers when taking beta carotene suggested a more favorable safety profile with the naturally occurring macular pigments lutein and zeaxanthin as compared with beta carotene. 81 Moreover, no statistical difference was noted between the 25-mg dose of zinc versus the 80-mg dose in the original AREDS formulation. 82 Current evidence shows that all AMD patients may be advised to increase the intake of leafy vegetables and to eat fatty fish at least 2 times a week. A Mediterranean type of diet may provide additional benefits in other age-related diseases beyond AMD. Patients with moderate or advanced AMD should be advised to use AREDS-based supplements. Current or past smokers must avoid supplements with beta carotene. As there were no adverse effects observed in many trials, it is advisable to use lutein/zeaxanthin AREDS-based supplements.
concLusions Currently, treatment options are available only for the late or "wet" form of AMD. For "dry" AMD, the use of antioxidants has been shown to delay progression in about one fourth of eyes. Understanding the modifiable risk factors and lifestyle changes can delay the onset of this potentially blinding disease to some extent. Molecular and genetic research has shed more light on the cellular events, genetic factors, and biochemical processes in the pathogenesis of early AMD. In future, we expect to witness newer biomarkers to predict the development of late AMD and thus help in prevention of visual impairment due to AMD. 
